Medication compliance and persistence: Terminology and definitions

Value in Health

Volumn 11, Issue 1, 2008, Pages 44-47

  Cramer, Joyce A ^a   Roy, Anuja ^b   Burrell, Anita ^c   Fairchild, Carol J ^d   Fuldeore, Mahesh J ^e   Ollendorf, Daniel A ^f   Wong, Peter K ^g  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c SANOFI   (France)

^d ALCON RESEARCH LTD   (United States)

^e TAP Pharmaceuticals   (United States)

^f PharMetrics Inc   (United States)

^g MERCY HEALTH PARTNERS   (United States)

Author keywords

Adherence; Compliance; Definitions; Persistence; Terminology

Indexed keywords

ARTICLE; DRUG USE; HUMAN; NOMENCLATURE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 38549098101     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00213.x     Document Type: Article

References (30)

1. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002 40 : 794 811.
2. Cramer JA. Partial medication compliance: the enigma in poor medical outcomes. Am J Manag Care 1995 1 : 45 52.
3. Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep 2000 2 : 510 14.
4. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: cross-national study. JAMA 1998 279 : 1458 62.
5. Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharm J 2004 272 : 1 40.
6. Urquhart J. Defining the margins for errors in patient compliance with prescribed drug regimens. Pharmacoepidemiol Drug 2000 9 : 565 8.
7. Hasford J. Biometric issues in measuring and analyzing partial compliance in clinical trials. In : Cramer, JA, Spilker, B, eds. Compliance in Medical Practice and Clinical Trials. New York : Raven Press, 1991.
8. Feinstein AR. On white coat effects and the electronic monitoring of compliance. Arch Intern Med 1990 150 : 1377 8.
9. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004 15 : 1003 8.
10. Sackett DL, Haynes RB. Compliance with Therapeutic Regimens. Baltimore, MD : The Johns Hopkins University Press, 1976.
11. Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Geneva : World Health Organization, 2003. Available from: http://www.who.int/ chronic_conditions/en/adherence_report.pdf [Accessed July 2, 2006].
12. Cramer JA. Relationship between medication compliance and medical outcomes. Am J Health Syst Pharm 1995 52 (Suppl. S52 9.
13. Lopatriello S, Berto P, Cramer JA, et al. Different aspects of adherence to antihypertensive treatments. Exp Rev Pharmacoeconom Res 2004 4 : 317 3.
14. Roter DL, Hall JA, Rolande M, et al. Effectiveness of interventions to improve patient adherence: a metaanalysis. Med Care 1998 36 (8 1138 61.
15. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990 150 : 1881 4.
16. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989 261 : 3273 7.
17. Claxton AJ, Cramer JA, Pierce C. Medication compliance: the importance of the dosing regimen. Clin Ther 2001 23 : 1296 310.
18. Catalan VS, LeLorier J. Predictors of long term persistence on statins in a subsidized clinical population. Value Health 2000 3 : 417 26.
19. Yanni F, Nichol MB, Yu AP, Ahn J. Persistence and adherence of medication for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005 8 : 495 505.
20. Cramer JA, Amonkar MM, Hebborn A, Altman RD. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005 21 : 1453 60.
21. White TJ, Chang E, Leslie S, et al. Patient adherence with HMG reductase inhibitor therapy among users of two types of prescription services. J Manag Care Pharm 2002 8 : 186 91.
22. Mauskopf JA, Paramore C, Lee WC, Snyder EH. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005 11 : 231 9.
23. Grant RW, O'Leary KM, Weilburg JB, et al. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004 164 : 2343 8.
24. Cramer JA, Sernyak M. Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate. Clin Ther 2004 26 : 905 14.
25. Malone M, Alger-Mayer SA. Pharmacist intervention enhances adherence to Orlistat therapy. Ann Pharmacother 2003 37 : 1598 602.
26. Carswell JL, Beard KA, Chevrette MM, et al. Tracking trends in secondary stroke prevention strategies. Ann Pharmacother 2004 38 : 215 19.
27. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005 11 : 449 57.
28. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records. Methods, validity, and applications. J Clin Epidemiol 1997 50 : 105 16.
29. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007 10 : 3 12.
30. Burrell A, Wong P, Ollendorf D, et al. Defining compliance/adherence and persistence: ISPOR Special Interest Working Group. Value Health 2005 8 : A194 5.